MDLZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mondelez International Inc (MDLZ) is not a strong buy at this moment for a long-term beginner investor with $50,000-$100,000 available for investment. While the company has strong emerging market growth potential and a robust dividend history, the near-term financial performance shows significant declines in net income, EPS, and gross margin. Additionally, technical indicators and options sentiment do not suggest a compelling entry point. A hold position is recommended until clearer positive signals emerge.
The MACD histogram is negative and expanding, suggesting bearish momentum. RSI is neutral at 40.906, indicating no clear overbought or oversold conditions. Moving averages are converging, showing a lack of strong directional trend. The current price of $57.25 is near the pivot level of $57.781, with key resistance at $59.022 and support at $56.539.
Strong growth potential in emerging markets, with significant revenue contributions from China, Brazil, and India.
A newly authorized $9 billion stock repurchase program to enhance shareholder value.
Long history of dividend increases, maintaining a quarterly dividend of $0.50 per share.
Significant declines in net income (-61.89% YoY), EPS (-60.77% YoY), and gross margin (-27.22% YoY) in Q4
Dividend payout ratio exceeding 100% of earnings, posing risks for income investors.
Bearish options sentiment and lack of strong technical buy signals.
Analysts highlight near-term threats, including softening volumes, tougher competition, and slower growth in key markets.
In Q4 2025, revenue increased by 9.29% YoY to $10.5 billion, but net income dropped sharply by 61.89% YoY to $665 million. EPS fell by 60.77% YoY to $0.51, and gross margin declined by 27.22% YoY to 27.83%. While revenue growth is positive, profitability metrics indicate significant challenges.
Analyst sentiment is mixed. Recent upgrades include BTIG's Buy rating with a $70 price target, citing long-term growth benefits and margin expansion. However, some analysts, like UBS and Rothschild, have downgraded the stock or lowered price targets due to near-term threats and margin pressures. Price targets range from $54 to $73, with a median around $65.
